Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)
| Status: | Completed |
|---|---|
| Conditions: | Atrial Fibrillation |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/4/2013 |
| Start Date: | August 2011 |
| End Date: | September 2015 |
| Contact: | Toll Free Number |
| Phone: | 1-888-577-8839 |
A Prospective Observational Registry Study to Characterise Normal Conditions of Use, Dosing and Safety Following Administration of Vernakalant IV Sterile Concentrate
This non-interventional prospective study is a post-authorization safety study (PASS) of
vernakalant conducted to collect information about normal conditions of use and appropriate
dosing, and to quantify possible medically significant risks associated with the use of
vernakalant in real-world clinical practice.
Inclusion Criteria:
- To be treated with intravenous vernakalant, independently of this study
- Participant and/or legal guardians willing to provide informed consent and/or
informed assent according to local regulations
Exclusion Criteria:
- Enrollment in an investigational drug or device clinical trial in the 30 days prior to
study enrolment. Participation in another non-interventional drug or device study or
registry is permitted.
We found this trial at
1
site
Click here to add this to my saved trials
